However, these LRRK2 inhibitors were mainly investigated in the context of LRRK2‐mutant PD, where increasing evidence also supports the role of LRRK2 in sporadic PD and familial PD without LRRK2 mutations. The gene discussed is LRRK2; the disease is Parkinson disease.